These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 33485094)

  • 21. The optimal duration of anticoagulant therapy after unprovoked venous thromboembolism - still a challenging issue.
    Elmi G; Di Pasquale G; Pesavento R
    Vasa; 2017 Mar; 46(2):87-95. PubMed ID: 28102773
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation Therapy for Venous Thromboembolism in the Real World　- From the COMMAND VTE Registry.
    Yamashita Y; Morimoto T; Amano H; Takase T; Hiramori S; Kim K; Konishi T; Akao M; Kobayashi Y; Inoue T; Oi M; Izumi T; Takahashi K; Tada T; Chen PM; Murata K; Tsuyuki Y; Sakai H; Saga S; Sasa T; Sakamoto J; Yamada C; Kinoshita M; Togi K; Ikeda T; Ishii K; Kaneda K; Mabuchi H; Otani H; Takabayashi K; Takahashi M; Shiomi H; Makiyama T; Ono K; Kimura T;
    Circ J; 2018 Apr; 82(5):1262-1270. PubMed ID: 29576597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal long-term pharmacological treatment of patients with venous thromboembolism that was unprovoked or associated with weak risk factors.
    Palareti G
    Expert Rev Hematol; 2017 Oct; 10(10):921-931. PubMed ID: 28803491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation after venous thromboembolism. Deciding on the optimal duration.
    Eichinger S
    Hamostaseologie; 2013 Aug; 33(3):211-7. PubMed ID: 23719863
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
    de Jong PG; Coppens M; Middeldorp S
    Br J Haematol; 2012 Aug; 158(4):433-41. PubMed ID: 22734929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative efficacy and safety of anticoagulants and aspirin for extended treatment of venous thromboembolism: A network meta-analysis.
    Sobieraj DM; Coleman CI; Pasupuleti V; Deshpande A; Kaw R; Hernandez AV
    Thromb Res; 2015 May; 135(5):888-96. PubMed ID: 25795564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism.
    Verhovsek M; Douketis JD; Yi Q; Shrivastava S; Tait RC; Baglin T; Poli D; Lim W
    Ann Intern Med; 2008 Oct; 149(7):481-90, W94. PubMed ID: 18838728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Duration of anticoagulation after venous thrombosis.
    Eichinger S; Kyrle PA
    Vasa; 2012 Jan; 41(1):11-7. PubMed ID: 22247055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How to predict recurrent venous thromboembolism and bleeding? A review of recent advances and their implications.
    Burggraaf JLI; van Rein N; Klok FA; Cannegieter SC
    Pol Arch Intern Med; 2023 May; 133(5):. PubMed ID: 37155155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data.
    Marcucci M; Iorio A; Douketis JD; Eichinger S; Tosetto A; Baglin T; Cushman M; Palareti G; Poli D; Tait RC; Kyrle PA
    J Thromb Haemost; 2015 May; 13(5):775-81. PubMed ID: 25660555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Extended anticoagulation after venous thromboembolism: should it be done?
    Fernandes CJ; Calderaro D; Piloto B; Hoette S; Jardim CVP; Souza R
    Ther Adv Respir Dis; 2019; 13():1753466619878556. PubMed ID: 31558116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: Communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease.
    den Exter PL; Woller SC; Robert-Ebadi H; Masias C; Morange PE; Castelli D; Hansen JB; Geersing GJ; Siegal DM; de Wit K; Klok FA
    J Thromb Haemost; 2022 Aug; 20(8):1910-1919. PubMed ID: 35735219
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis.
    Khan F; Rahman A; Carrier M; Kearon C; Weitz JI; Schulman S; Couturaud F; Eichinger S; Kyrle PA; Becattini C; Agnelli G; Brighton TA; Lensing AWA; Prins MH; Sabri E; Hutton B; Pinede L; Cushman M; Palareti G; Wells GA; Prandoni P; Büller HR; Rodger MA;
    BMJ; 2019 Jul; 366():l4363. PubMed ID: 31340984
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Models for predicting venous thromboembolism in ambulatory patients with lung cancer: a systematic review protocol.
    Yan AR; Samarawickrema I; Naunton M; Peterson GM; Yip D; Mortazavi R
    BMJ Open; 2021 Dec; 11(12):e055322. PubMed ID: 34853112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Venous thromboembolism: Predicting recurrence and the need for extended anticoagulation.
    Barnes GD; Kanthi Y; Froehlich JB
    Vasc Med; 2015 Apr; 20(2):143-52. PubMed ID: 25832602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review.
    Gómez-Outes A; Lecumberri R; Suárez-Gea ML; Terleira-Fernández AI; Monreal M; Vargas-Castrillón E
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):490-500. PubMed ID: 25802423
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of tailoring anticoagulant treatment duration by applying a recurrence risk prediction model in patients with venous thromboembolism compared to usual care: A randomized controlled trial.
    Geersing GJ; Hendriksen JMT; Zuithoff NPA; Roes KC; Oudega R; Takada T; Schutgens REG; Moons KGM
    PLoS Med; 2020 Jun; 17(6):e1003142. PubMed ID: 32589630
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Editor's Choice - A Systematic Review and Meta-Analysis of the Efficacy and Safety of Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer.
    Kirkilesis GI; Kakkos SK; Tsolakis IA
    Eur J Vasc Endovasc Surg; 2019 May; 57(5):685-701. PubMed ID: 31097186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Claims-Based Score for the Prediction of Bleeding in a Contemporary Cohort of Patients Receiving Oral Anticoagulation for Venous Thromboembolism.
    Alonso A; Norby FL; MacLehose RF; Zakai NA; Walker RF; Adam TJ; Lutsey PL
    J Am Heart Assoc; 2021 Sep; 10(18):e021227. PubMed ID: 34514806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deciding on Treatment Duration for Unprovoked Venous Thromboembolism: What is Important to Patients?
    van de Brug A; de Winter MA; Ten Wolde M; Kaasjager K; Nijkeuter M
    Thromb Haemost; 2022 Apr; 122(4):600-610. PubMed ID: 34169494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.